VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.5 EUR | -3.37% |
|
-2.58% | -7.71% |
| Mar. 20 | Vetoquinol SA Proposes Dividend | CI |
| Mar. 20 | Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 529M 563M | Sales 2024 * | 553M 587M | Capitalization | 1.12B 1.19B |
|---|---|---|---|---|---|
| Net income 2023 | 55M 58.46M | Net income 2024 * | 56M 59.52M | EV / Sales 2023 | 2.29 x |
| Net cash position 2023 * | 125M 132M | Net cash position 2024 * | 184M 195M | EV / Sales 2024 * | 1.69 x |
| P/E ratio 2023 * |
20.3
x | P/E ratio 2024 * |
19.6
x | Employees | 2,497 |
| Yield 2023 |
0.83% | Yield 2024 * |
0.86% | Free-Float | 32.58% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.37% | ||
| 1 week | -2.58% | ||
| Current month | -5.03% | ||
| 1 month | -10.34% | ||
| 3 months | -10.34% | ||
| 6 months | +15.38% | ||
| Current year | -7.71% |
1 week
93.20
98.30
1 month
93.20102.80
Current year
93.20110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 94.5 | -3.37% | 1,760 |
| 24-04-17 | 97.8 | +1.24% | 17,816 |
| 24-04-16 | 96.6 | -0.72% | 4,570 |
| 24-04-15 | 97.3 | +1.57% | 7,563 |
| 24-04-12 | 95.8 | -1.24% | 4,250 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
94.5
EUR
Average target price
108.6
EUR
Spread / Average Target
+14.97%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.71% | 1.19B | |
| -8.93% | 6.69B | |
| +13.00% | 3.35B | |
| +3.76% | 3.33B | |
| +2.87% | 1.46B | |
| -17.92% | 1.33B | |
| -28.92% | 1.19B | |
| -17.76% | 1.08B | |
| -3.84% | 1.01B | |
| -1.98% | 868M |
- Stock Market
- Equities
- VETO Stock
